Search

Agriculture and forestry are fundamental industries. With the development of the ESG concept, stakeholders are increasingly concerned about the relationship between ESG and agricultural and forestry corporate performance. This paper examines 156 listed agricultural and forestry companies to explore the impact of ESG on corporate performance, both theoretically and empirically, using two-stage least squares. Heterogeneity is explored from the perspective of three sub-dimensions of ESG and industry comparison, respectively. Finally, the impact mechanism of ESG is analyzed from three perspectives: government, market, and company. Results indicate that (1) ESG and corporate performance are significantly and positively correlated, and higher ESG ratings are beneficial to corporate performance improvement. (2) Compared with E performance, S and G performance are more conducive to promoting corporate performance growth. (3) There is no significant difference in the effect of ESG on corporate performance between listed companies in agriculture and forestry. (4) Tax incentives and the regional marketization degree have a negative moderating effect, but the proportion of female executives plays a positive moderating role. These findings provide useful insights for listed companies in agriculture and forestry to improve ESG performance and, consequently, corporate performance, and also promote listed companies to play a greater leading role in green development.

DDR1 has been identified as a cancer-associated receptor tyrosine kinase that is highly expressed in several malignancies relative to normal tissues. Clinically approved multi-kinase inhibitors, such as nilotinib, inhibit DDR1-mediated tumor growth in xenograft models, suggesting DDR1 might be a potential target for cancer treatments. Here, we employed an antibody-based strategy with a novel anti-DDR1 antibody-drug conjugate (ADC) for colon carcinoma treatment. We developed T4 H11 -DM4, an ADC targeting DDR1 which carries the tubulin inhibitor payload DM4. Immunohistochemical analysis of a tissue microarray containing 100 colon cancer specimens revealed that DDR1 was highly expressed in 81% of tumor tissues. Meanwhile, high expression of DDR1 was associated with poor survival in patients. In vitro, T4 H11 -DM4 exhibited potent anti-proliferative activity with half maximal inhibitory concentration (IC50 ) values in the nanomolar range in a panel of colon cancer cell lines. In vivo, the antitumor efficacy of T4 H11 -DM4 was evaluated in three colon cancer cell lines expressing different levels of DDR1. T4 H11 -DM4 achieved complete tumor regression at doses of 5 and 10 mg·kg-1 in HT-29 and HCT116 tumor models. Moreover, a correlation between in vivo efficacy of T4 H11 -DM4 and the levels of DDR1 expression on the cell surface was observed. Tumor cell proliferation was caused by the induction of mitotic arrest, indicating that the antitumor effect in vivo was mediated by DM4. In addition, T4 H11 -DM4 was efficacious in oxaliplatin-resistant colon cancer models. In exploratory safety studies, T4 H11 -DM4 exhibited no overt toxicities when multi-doses were administered at 10 mg·kg-1 into BALB/c nude mice or when a single dose up to 50 mg·kg-1 was administered into BALB/c mice. Overall, our findings highlight the potential of DDR1-targeted ADC and may facilitate the development of a new effective therapeutic strategy for colon cancer.